Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Orphenadrine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Orphenadrine | hsa00190 | Oxidative phosphorylation | 5.61E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Orphenadrine | hsa00230 | Purine metabolism | 1.81E-02 | 2 | P20839, Q02153 | IMPDH1, GUCY1B3 | More | | Orphenadrine | hsa00260 | Glycine, serine and threonine metabolism | 1.99E-02 | 1 | P22557 | ALAS2 | More | | Orphenadrine | hsa00310 | Lysine degradation | 1.53E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Orphenadrine | hsa00562 | Inositol phosphate metabolism | 2.54E-03 | 4 | P27987, Q13572, Q96PE3, P42338 | ITPKB, ITPK1, INPP4A, PIK3CB | More | | Orphenadrine | hsa00565 | Ether lipid metabolism | 3.94E-02 | 1 | Q8N661 | TMEM86B | More | | Orphenadrine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Orphenadrine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Orphenadrine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | Orphenadrine | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | | Orphenadrine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Orphenadrine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Orphenadrine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Orphenadrine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Orphenadrine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Orphenadrine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Orphenadrine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Orphenadrine | hsa03013 | RNA transport | 9.68E-04 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Orphenadrine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Orphenadrine | hsa03040 | Spliceosome | 3.94E-04 | 8 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q01130, O43447 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS2, PPIH | More | | Orphenadrine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Orphenadrine | hsa04014 | Ras signaling pathway | 3.62E-02 | 5 | P42338, P49767, P0DP23, P63218, P50151 | PIK3CB, VEGFC, CALM1, GNG5, GNG10 | More | | Orphenadrine | hsa04020 | Calcium signaling pathway | 5.15E-05 | 8 | P27987, P21796, Q16566, P30679, O15399, P0DP23, P23634, P49767 | ITPKB, VDAC1, CAMK4, GNA15, GRIN2D, CALM1, ATP2B4, VEGFC | More | | Orphenadrine | hsa04024 | cAMP signaling pathway | 1.49E-02 | 5 | P42338, P0DP23, P23634, Q16566, O15399 | PIK3CB, CALM1, ATP2B4, CAMK4, GRIN2D | More | | Orphenadrine | hsa04070 | Phosphatidylinositol signaling system | 1.49E-03 | 5 | P0DP23, P42338, Q96PE3, Q13572, P27987 | CALM1, PIK3CB, INPP4A, ITPK1, ITPKB | More | | Orphenadrine | hsa04071 | Sphingolipid signaling pathway | 2.55E-03 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Orphenadrine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Orphenadrine | hsa04120 | Ubiquitin mediated proteolysis | 2.51E-03 | 6 | Q14145, Q13042, P62837, Q15751, O95071, P0CG47 | KEAP1, CDC16, UBE2D2, HERC1, UBR5, UBB | More | | Orphenadrine | hsa04137 | Mitophagy - animal | 9.52E-03 | 2 | Q07817, P0CG47 | BCL2L1, UBB | More | | Orphenadrine | hsa04145 | Phagosome | 1.66E-03 | 9 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Orphenadrine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | Orphenadrine | hsa04217 | Necroptosis | 2.24E-04 | 12 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | Orphenadrine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Orphenadrine | hsa04371 | Apelin signaling pathway | 7.45E-03 | 5 | P63218, P50151, Q13485, Q16566, P0DP23 | GNG5, GNG10, SMAD4, CAMK4, CALM1 | More | | Orphenadrine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Orphenadrine | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | | Orphenadrine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Orphenadrine | hsa04613 | Neutrophil extracellular trap formation | 2.15E-05 | 11 | P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Orphenadrine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Orphenadrine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | | Orphenadrine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | Orphenadrine | hsa04664 | Fc epsilon RI signaling pathway | 2.32E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | | Orphenadrine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.78E-03 | 7 | P07948, P42338, P23528, P06396, O14494, P14598, P17252 | LYN, PIK3CB, CFL1, GSN, PLPP1, NCF1, PRKCA | More | | Orphenadrine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Orphenadrine | hsa04672 | Intestinal immune network for IgA production | 1.62E-02 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Orphenadrine | hsa04713 | Circadian entrainment | 8.43E-03 | 4 | O15399, P0DP23, P63218, P50151 | GRIN2D, CALM1, GNG5, GNG10 | More | | Orphenadrine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Orphenadrine | hsa04720 | Long-term potentiation | 1.63E-02 | 3 | Q16566, P0DP23, O15399 | CAMK4, CALM1, GRIN2D | More | | Orphenadrine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Orphenadrine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Orphenadrine | hsa04724 | Glutamatergic synapse | 4.10E-02 | 3 | O15399, P63218, P50151 | GRIN2D, GNG5, GNG10 | More | | Orphenadrine | hsa04725 | Cholinergic synapse | 5.94E-03 | 4 | P63218, P50151, Q16566, P42338 | GNG5, GNG10, CAMK4, PIK3CB | More | | Orphenadrine | hsa04726 | Serotonergic synapse | 1.52E-02 | 4 | P63218, P50151, P33260, P09917 | GNG5, GNG10, CYP2C18, ALOX5 | More | | Orphenadrine | hsa04728 | Dopaminergic synapse | 4.47E-02 | 4 | P63218, P50151, P0DP23, O00327 | GNG5, GNG10, CALM1, ARNTL | More | | Orphenadrine | hsa04744 | Phototransduction | 2.80E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Orphenadrine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Orphenadrine | hsa04916 | Melanogenesis | 4.80E-02 | 4 | P0DP23, Q9UJU2, P17252, P04628 | CALM1, LEF1, PRKCA, WNT1 | More | | Orphenadrine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Orphenadrine | hsa04925 | Aldosterone synthesis and secretion | 3.14E-02 | 3 | P0DP23, Q16566, P23634 | CALM1, CAMK4, ATP2B4 | More | | Orphenadrine | hsa04926 | Relaxin signaling pathway | 3.93E-04 | 8 | P42338, P63218, P50151, P18848, P22694, P49767, P14780, P30679 | PIK3CB, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, GNA15 | More | | Orphenadrine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Orphenadrine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Orphenadrine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Orphenadrine | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | Orphenadrine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Orphenadrine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Orphenadrine | hsa05017 | Spinocerebellar ataxia | 5.94E-03 | 4 | Q8TB72, O15399, P42338, P21796 | PUM2, GRIN2D, PIK3CB, VDAC1 | More | | Orphenadrine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Orphenadrine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Orphenadrine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Orphenadrine | hsa05034 | Alcoholism | 6.66E-06 | 12 | O15399, Q16566, Q13547, P0DP23, P63218, P50151, Q93077, P58876, P62807, Q16778, O60814, P68431 | GRIN2D, CAMK4, HDAC1, CALM1, GNG5, GNG10, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Orphenadrine | hsa05132 | Salmonella infection | 2.93E-02 | 10 | P51617, Q9UJU2, Q13489, P10415, O75369, O60603, Q9BQS8, Q13561, Q13509, P68371 | IRAK1, LEF1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Orphenadrine | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | | Orphenadrine | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | | Orphenadrine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Orphenadrine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Orphenadrine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | | Orphenadrine | hsa05150 | Staphylococcus aureus infection | 1.91E-02 | 4 | Q14532, P59665, P59666, P49913 | KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | | Orphenadrine | hsa05152 | Tuberculosis | 5.68E-03 | 9 | Q13488, P0DP23, P48382, O60603, P10415, P13765, P01568, Q9UDY8, P51617 | TCIRG1, CALM1, RFX5, TLR2, BCL2, HLA-DOB, IFNA21, MALT1, IRAK1 | More | | Orphenadrine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Orphenadrine | hsa05163 | Human cytomegalovirus infection | 4.19E-02 | 5 | P42338, P63218, P50151, P0DP23, P30101 | PIK3CB, GNG5, GNG10, CALM1, PDIA3 | More | | Orphenadrine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.19E-02 | 5 | P42338, P63218, P50151, P07948, P0DP23 | PIK3CB, GNG5, GNG10, LYN, CALM1 | More | | Orphenadrine | hsa05168 | Herpes simplex virus 1 infection | 6.00E-04 | 16 | P25963, P01568, Q05823, P42224, Q07955, Q01130, Q13243, Q13489, Q9Y2A4, Q13398, P51522, Q9HCX3, P17038, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF443, ZNF211, ZNF83, ZNF304, ZNF43, ZNF140, ZNF189, ZNF212 | More | | Orphenadrine | hsa05170 | Human immunodeficiency virus 1 infection | 6.97E-04 | 16 | P42338, P62873, P63218, P50151, P0DP23, P17252, O00463, P30101, Q14643, P01568, P51617, O60603, P23528, P10415, Q93034, Q9Y6Q5 | PIK3CB, GNB1, GNG5, GNG10, CALM1, PRKCA, TRAF5, PDIA3, ITPR1, IFNA21, IRAK1, TLR2, CFL1, BCL2, CUL5, AP1M2 | More | | Orphenadrine | hsa05202 | Transcriptional misregulation in cancer | 4.29E-03 | 15 | Q12778, Q15532, P14780, P27930, P14923, Q16548, P11215, Q13489, Q13077, P35226, P05164, P08246, Q9C0K0, Q13547, P12980 | FOXO1, SS18, MMP9, IL1R2, JUP, BCL2A1, ITGAM, BIRC3, TRAF1, BMI1, MPO, ELA2, BCL11B, HDAC1, LYL1 | More | | Orphenadrine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Orphenadrine | hsa05204 | Chemical carcinogenesis | 1.61E-03 | 3 | P78417, P11712, P33260 | GSTO1, CYP2C9, CYP2C18 | More | | Orphenadrine | hsa05205 | Proteoglycans in cancer | 1.39E-03 | 13 | Q13009, Q12955, Q14643, O75369, P14780, P17252, O60603, P01375, P23588, P04628, Q13635, P22694, P08962 | TIAM1, ANK3, ITPR1, FLNB, MMP9, PRKCA, TLR2, TNF, EIF4B, WNT1, PTCH1, PRKACB, CD63 | More | | Orphenadrine | hsa05214 | Glioma | 2.32E-02 | 3 | P0DP23, Q16566, P42338 | CALM1, CAMK4, PIK3CB | More | | Orphenadrine | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | Orphenadrine | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | | Orphenadrine | hsa05320 | Autoimmune thyroid disease | 8.64E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Orphenadrine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Orphenadrine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Orphenadrine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Orphenadrine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | Orphenadrine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | Orphenadrine | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | Orphenadrine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | |